Twist Bioscience $17M Securities Class Action Settlement

Twist Bioscience $17M Securities Class Action SettlementInvestors who bought Twist Bioscience stock between Dec. 20, 2018, and Nov. 15, 2022, may be eligible to claim a cash payment from a class action settlement.Twist Bioscience $17M Securities Class Action SettlementWeekly NewsletterClass actions settlements delivered to your inbox.Thank you! Check your inbox for a welcome email.Oops! Something went wrong while submitting the form.William C. GendronEditor in ChiefPublishedSeptember 8, 2026 10:44 AMUpdatedSeptember 8, 2026Join the DiscussionInvestors who purchased or otherwise acquired Twist Bioscience Corp. common stock between Dec. 20, 2018, and Nov. 15, 2022, or in the company's December 2020 secondary offering at $110 per share may be eligible to claim a cash payment from a class action settlement.Twist Bioscience and certain executives agreed to pay $17 million to settle a securities class action lawsuit alleging they made false and misleading statements about the company's production process, product quality and accounting. The lawsuit claimed those statements inflated the price of Twist common stock and caused investor losses when corrective information reached the market on Nov. 15, 2022.Who can file a claim?The settlement class includes all persons and entities who purchased or otherwise acquired Twist common stock in the December 2020 offering pursuant to the 2020 registration statement or between Dec. 20, 2018, and Nov. 15, 2022, inclusive, and suffered damages as a result.Additional detailsBoth individuals and entities can be class members.The settlement includes investors who held stock in their own name and those who held through a broker or other nominee.The beneficial owner or a legal representative must submit the claim.Joint owners must each sign the claim form.Executors, administrators, guardians, conservators and trustees may submit claims on behalf of others and must provide proof of authority.